EUVIMEDEUVIMED entdecken
Crossref

Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor

Scott Throner, Tianshu Feng, Jannik N Andersen, Madhavi Bandi, Justin L Engel, Shanzhong Gong, Deepali Gotur, Lina Gu, Alan Huang, Katherine Lazarides, John P Maxwell, Patrick McCarren und 8 weitere

Bioorganic & Medicinal Chemistry Letters · 2025

DOI: 10.1016/j.bmcl.2025.130262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2025. Verfasst von Scott Throner und 19 weiteren Autor:innen. Beteiligte Einrichtung: Tango Therapeutics, 201 Brookline Ave, Boston, MA 02215, United States. Hauptthemen laut MEDLINE: Ubiquitin-Specific Proteases, Drug Discovery, Antineoplastic Agents, Protease Inhibitors. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

USP1 (ubiquitin-specific peptidase 1) is a deubiquitinating enzyme that has been identified as essential in BRCA1/2 mutant cells and implicated in the DNA damage response. Inhibition of USP1 by small molecule inhibitors disrupts DNA repair and replication and is being pursued as a potential anticancer therapeutic in BRCA1/2 mutant cancers. We report the discovery of an in vitro and in vivo USP1 inhibitor tool compound TNG-6132 (18), a reversible, allosteric inhibitor of USP1, which strongly inhibits USP1 enzymatic activity. This inhibitory effect translates into in vitro cellular viability defects in a BRCA1-mutant breast cancer cell line, as well as an in vivo pharmacodynamic (PD) response and tumor growth suppression in a mouse xenograft efficacy model. Additionally, we report an X-ray co-crystal structure of TNG-6132 (18) bound in the USP1-UAF1 complex, a result that furthered our understanding of the role played by key elements of the pharmacophore of this chemotype as well as its mechanism of inhibition of USP1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Specific ProteasesDrug DiscoveryAntineoplastic AgentsProtease InhibitorsHumansAnimalsMiceStructure-Activity RelationshipAdministration, OralMolecular StructureCell Line, TumorDose-Response Relationship, DrugCrystallography, X-RayBiological AvailabilityFemale

Stichwörter der Autor:innen

BRCA1/2 mutantDUBSynthetic lethalityUSP1

Substanzen

Ubiquitin-Specific ProteasesUSP1 protein, humanAntineoplastic AgentsProtease Inhibitors

Autor:innen und Institutionen

  • Tango Therapeutics, 201 Brookline Ave, Boston, MA 02215, United States.

Zitieren

APA

Throner, S., Feng, T., Andersen, J. N., Bandi, M., Engel, J. L., Gong, S., Gotur, D., Gu, L., Huang, A., Lazarides, K., Maxwell, J. P., McCarren, P., McMillan, B. J., Pham, T. V., Simoneau, A., Tsai, A., Whittington, D. A., Wilker, E., Zhang, M., & Zhang, W. (2025). Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2025.130262

Vancouver

Throner S, Feng T, Andersen JN, Bandi M, Engel JL, Gong S, et al. Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor. Bioorganic & Medicinal Chemistry Letters. 2025. doi:10.1016/j.bmcl.2025.130262

BibTeX
@article{Throner2025,
  author = {Throner, Scott and Feng, Tianshu and Andersen, Jannik N and Bandi, Madhavi and Engel, Justin L and Gong, Shanzhong and Gotur, Deepali and Gu, Lina and Huang, Alan and Lazarides, Katherine and Maxwell, John P and McCarren, Patrick and McMillan, Brian J and Pham, Truc V and Simoneau, Antoine and Tsai, Alice and Whittington, Douglas A and Wilker, Erik and Zhang, Minjie and Zhang, Wenhai},
  title = {Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2025},
  doi = {10.1016/j.bmcl.2025.130262}
}
Kostenlos starten →